about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Bounc­ing from ma­jor set­back, Sum­mit hands out $500M cash for can­cer drug — thanks to a loan from bil­lion­aire CEO

3 years ago
Financing
Deals

As FDA door shuts on its PI3K, MEI Phar­ma throws in the tow­el, lays off staff

3 years ago
People
R&D

Nkar­ta un­der­scores safe­ty of CAR-NK, boasts ear­ly re­spons­es

3 years ago
R&D
Cell/Gene Tx

Af­ter M&A fell through, Ther­a­peu­tic­sMD sells hor­mone ther­a­py, con­tra­cep­tive ring for $140M cash plus roy­al­ties

3 years ago
Deals

Big week for Alzheimer’s da­ta; As­traZeneca buys cell ther­a­py start­up; Dig­i­tal ther­a­peu­tics hits a pay­er wall; and ...

3 years ago
Weekly

FDA re­jects Y-mAbs’ neu­rob­las­toma drug af­ter tak­ing is­sue with clin­i­cal tri­al de­sign

3 years ago
R&D
FDA+

Rigel Phar­ma scores FDA ap­proval for leukemia, kick­ing off show­down with Servi­er in IDH1

3 years ago
FDA+

SQZ Biotech slash­es head­count by 60% as founder/CEO hits ex­it — while Syn­log­ic lays off 25%

3 years ago
People
R&D

Sana, Codex­is lay off staff, reshuf­fle pipeline in bid to fo­cus cell ther­a­py, en­zyme en­gi­neer­ing work

3 years ago
People

PhI­Ib win puts Nim­bus one step clos­er to chal­leng­ing Bris­tol My­ers in TYK2

3 years ago
R&D

Hori­zon Ther­a­peu­tics in takeover talks with Am­gen, J&J, Sanofi as po­ten­tial buy­ers

3 years ago
Deals

Boehringer In­gel­heim buys CD38 drug; Mer­ck bets on ma­chine learn­ing in an­ti­body de­sign

3 years ago
News Briefing

New TIG­IT da­ta cut from Gilead, Ar­cus sets the stage for full read­out

3 years ago
R&D

With ops span­ning Bel­gium and Chi­na, Full-Life inks $245M buy­out to beef up ra­dio­phar­ma pipeline

3 years ago
Deals

Up­dat­ed: As­traZeneca jumps deep­er in­to cell ther­a­py 2.0 space with $320M biotech M&A

3 years ago
Deals
Cell/Gene Tx

San Diego biotech lands $120M to launch a slate of tri­als in neu­rosen­so­ry dis­or­ders

3 years ago
Financing

In new deal, As­traZeneca places small bet on 'crit­i­cal but chal­leng­ing' tar­get

3 years ago
Deals

Big Phar­ma's Twit­ter ex­o­dus; Mer­ck wa­gers $1.35B on buy­out; $3.5M gene ther­a­py; and more

3 years ago
Weekly

One hur­dle down? FDA won't hold ad­comm for Bio­Mar­in's he­mo­phil­ia gene ther­a­py af­ter all

3 years ago
Cell/Gene Tx

CSL lands FDA ap­proval for he­mo­phil­ia B gene ther­a­py, sets $3.5M list price

3 years ago
Cell/Gene Tx
FDA+

Cy­cle­ri­on board quick­ly nix­es CEO Pe­ter Hecht's un­ortho­dox pitch for low cash re­serves

3 years ago
People
Deals

Sim­u­la­tions for ex­per­i­ments: Bay­er-backed start­up lands $20M to test out its tech

3 years ago
Financing
Startups

Days af­ter re­port­ing PhI­II fail­ure, GSK pulls BC­MA drug from US mar­ket — but it's not giv­ing up en­tire­ly yet

3 years ago
Pharma
FDA+

With the clin­ic in sight, Greg Verdine's start­up bags $178M for new class of tar­get­ed ther­a­pies

3 years ago
Financing
Startups
First page Previous page 19202122232425 Next page Last page
A service from the Financial Times